...
search icon
crdf-img

Cardiff Oncology Inc, Common Stock

CRDF

NAQ

$2.95

+$0.07

(2.43%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$187.60M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
735.77K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.73
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.01 L
$5.64 H
$2.95

About Cardiff Oncology Inc, Common Stock

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company's lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCRDFSectorS&P500
1-Week Return4.61%4.13%7.14%
1-Month Return-10.33%-4.48%-0.92%
3-Month Return-13.74%-5.78%-8.95%
6-Month Return-1.34%-7.23%-5.21%
1-Year Return-33.86%-1.69%7.95%
3-Year Return120.15%3.23%28.74%
5-Year Return165.77%38.7%92.67%
10-Year Return-99.49%88.08%161.14%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue365.99K359.00K386.00K488.00K683.00K[{"date":"2020-12-31","value":53.59,"profit":true},{"date":"2021-12-31","value":52.56,"profit":true},{"date":"2022-12-31","value":56.52,"profit":true},{"date":"2023-12-31","value":71.45,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue11.23M500.00K200.00K32.86M-[{"date":"2020-12-31","value":34.19,"profit":true},{"date":"2021-12-31","value":1.52,"profit":true},{"date":"2022-12-31","value":0.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(10.87M)(141.00K)186.00K488.00K683.00K[{"date":"2020-12-31","value":-1591.36,"profit":false},{"date":"2021-12-31","value":-20.64,"profit":false},{"date":"2022-12-31","value":27.23,"profit":true},{"date":"2023-12-31","value":71.45,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(2969.73%)(39.28%)48.19%100.00%100.00%[{"date":"2020-12-31","value":-2969.73,"profit":false},{"date":"2021-12-31","value":-39.28,"profit":false},{"date":"2022-12-31","value":48.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses19.45M29.21M40.29M45.90M49.33M[{"date":"2020-12-31","value":39.43,"profit":true},{"date":"2021-12-31","value":59.22,"profit":true},{"date":"2022-12-31","value":81.66,"profit":true},{"date":"2023-12-31","value":93.04,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(19.09M)(28.86M)(39.90M)(45.41M)(48.65M)[{"date":"2020-12-31","value":-1908587400,"profit":false},{"date":"2021-12-31","value":-2885500000,"profit":false},{"date":"2022-12-31","value":-3990200000,"profit":false},{"date":"2023-12-31","value":-4541200000,"profit":false},{"date":"2024-12-31","value":-4865100000,"profit":false}]
Total Non-Operating Income/Expense(132.38K)828.00K2.78M7.77M6.46M[{"date":"2020-12-31","value":-1.7,"profit":false},{"date":"2021-12-31","value":10.65,"profit":true},{"date":"2022-12-31","value":35.76,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":83.05,"profit":true}]
Pre-Tax Income(19.31M)(28.29M)(38.70M)(41.44M)(45.45M)[{"date":"2020-12-31","value":-1930667200,"profit":false},{"date":"2021-12-31","value":-2829100000,"profit":false},{"date":"2022-12-31","value":-3870400000,"profit":false},{"date":"2023-12-31","value":-4144100000,"profit":false},{"date":"2024-12-31","value":-4545500000,"profit":false}]
Income Taxes(26.73K)(549.00K)(1.20M)230.10K-[{"date":"2020-12-31","value":-11.61,"profit":false},{"date":"2021-12-31","value":-238.59,"profit":false},{"date":"2022-12-31","value":-520.63,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(19.28M)(27.74M)(37.51M)(41.67M)-[{"date":"2020-12-31","value":-1927994700,"profit":false},{"date":"2021-12-31","value":-2774200000,"profit":false},{"date":"2022-12-31","value":-3750600000,"profit":false},{"date":"2023-12-31","value":-4167110500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(19.28M)(28.29M)(38.70M)(40.80M)(45.43M)[{"date":"2020-12-31","value":-1927842800,"profit":false},{"date":"2021-12-31","value":-2829100000,"profit":false},{"date":"2022-12-31","value":-3870400000,"profit":false},{"date":"2023-12-31","value":-4080100000,"profit":false},{"date":"2024-12-31","value":-4543100000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(19.28M)(27.74M)(37.51M)(41.44M)(45.43M)[{"date":"2020-12-31","value":-1927994700,"profit":false},{"date":"2021-12-31","value":-2774200000,"profit":false},{"date":"2022-12-31","value":-3750600000,"profit":false},{"date":"2023-12-31","value":-4144100000,"profit":false},{"date":"2024-12-31","value":-4543100000,"profit":false}]
EPS (Diluted)(1.30)(0.71)(0.89)(0.93)(0.94)[{"date":"2020-12-31","value":-130,"profit":false},{"date":"2021-12-31","value":-71,"profit":false},{"date":"2022-12-31","value":-89,"profit":false},{"date":"2023-12-31","value":-93,"profit":false},{"date":"2024-12-31","value":-94,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRDF
Cash Ratio 6.83
Current Ratio 7.08

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRDF
ROA (LTM) -34.01%
ROE (LTM) -59.51%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRDF
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRDF
Trailing PE NM
Forward PE NM
P/S (TTM) 287.33
P/B 2.37
Price/FCF NM
EV/R 155.23
EV/Ebitda NM

FAQs

What is Cardiff Oncology Inc share price today?

Cardiff Oncology Inc (CRDF) share price today is $2.95

Can Indians buy Cardiff Oncology Inc shares?

Yes, Indians can buy shares of Cardiff Oncology Inc (CRDF) on Vested. To buy Cardiff Oncology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRDF stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cardiff Oncology Inc be purchased?

Yes, you can purchase fractional shares of Cardiff Oncology Inc (CRDF) via the Vested app. You can start investing in Cardiff Oncology Inc (CRDF) with a minimum investment of $1.

How to invest in Cardiff Oncology Inc shares from India?

You can invest in shares of Cardiff Oncology Inc (CRDF) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRDF stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cardiff Oncology Inc shares
What is Cardiff Oncology Inc 52-week high and low stock price?

The 52-week high price of Cardiff Oncology Inc (CRDF) is $5.64. The 52-week low price of Cardiff Oncology Inc (CRDF) is $2.01.

What is Cardiff Oncology Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cardiff Oncology Inc (CRDF) is 2.37

What is the Market Cap of Cardiff Oncology Inc?

The market capitalization of Cardiff Oncology Inc (CRDF) is $187.60M

What is Cardiff Oncology Inc’s stock symbol?

The stock symbol (or ticker) of Cardiff Oncology Inc is CRDF

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top